Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Did Immunovant (NASDAQ:IMVT) Rally 15.1% on Its Rheumatoid Arthritis Trial Win?

The result gives the company a path into a large market where patients have run out of options, and it validates the drug in a disease where FcRn blockers had not been proven. A randomisedWithdrawaldesign is a demanding test, because it measures whether patients …

Vinay Lochav | 10 November 2026

Why Is Parabolic Technologies (NASDAQ:PARA) Dropping 14.74% Pre-Market on Tuesday?

The pressure is tied to a financing and a listing problem, not to a new operating release. The prospectus describes a USD 13.5 million underwritten offering of units with warrants exercisable at USD 6.80, an 8.0% underwriter fee plus USD 125,000 of legal fees, …

Vinay Lochav | 10 November 2026

Why Did Vir Biotechnology (NASDAQ:VIR) Rise About 13% on Phase 3 Hepatitis Delta Success?

The strength and consistency of the data across endpoints reduced the main uncertainty around the programme of Vir Biotechnology (NASDAQ:VIR). Results in cirrhotic patients, the hardest group to treat, were as strong as in the overall population, with 85% achieving undetectable virus against 73% …

Vinay Lochav | 10 November 2026

Why Is Frontier Nuclear and Minerals (NASDAQ:FNUC) Sliding 14% Pre-Market on Tuesday?

No company release, filing, trial result, offering or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. The most recent dated items found were the March 18, 2026 …

Vinay Lochav | 10 November 2026

Why Did Faeth Therapeutics (NASDAQ:FTH) Crash 42.5% on Its Endometrial Cancer Data?

The scale of the fall suggests investors had priced in a stronger efficacy signal. A 33% confirmed response rate is respectable for a late-line population, but the comparison that matters is with paclitaxel alone and with other targeted options, and a single-arm study of …

Vinay Lochav | 10 November 2026

Why Is Founder Group (NASDAQ:FGL) Dropping 14% Pre-Market on Tuesday?

No company release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. Recent dated items include the October 23, 2026 notice that the company regained compliance …

Vinay Lochav | 10 November 2026

Why Did Janux Therapeutics (NASDAQ:JANX) Slump After Its First JANX011 Data?

The safety profile was clean, with only Grade 1 cytokine release events and no serious adverse events, but the depth of effect was less consistent than investors appear to have hoped. At the top 3 mg dose, depletion of more than 90% was seen …

Vinay Lochav | 10 November 2026

Why Is NetClass Technology (NASDAQ:NTCL) Plunging 14% Pre-Market on Tuesday?

No company release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. Dated items found include the October 2026 announcement of a move into AI companion …

Vinay Lochav | 10 November 2026

Why Did monday.com (NASDAQ:MNDY) Fall About 7% Despite a 19% Revenue Rise?

Key Highlightsmonday.com (NASDAQ:MNDY) shares fell about 7% on November 9, 2026, with intraday estimates ranging from 5% to 9%, after third-quarter results.Third-quarterRevenuerose 19% to USD 377.5 million, ahead of the USD 369.2 million consensus, and adjustedEarnings Per Sharereached USD 2.14.Fourth-quarter revenue guidance of USD …

Vinay Lochav | 10 November 2026

Why Is Yueda Digital (NASDAQ:YDKG) Falling 13% Pre-Market on Tuesday?

No company release, filing or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. Dated items found include the June 10, 2026 Solon Initiative, an AI agent andStablecoinpayments …

Vinay Lochav | 10 November 2026
Support

Hi! How can we help you today?

Loading…